HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Citrucel Claim That Metamucil Causes Excess Gas Expelled After 20 Years

This article was originally published in The Rose Sheet

Executive Summary

GlaxoSmithKline will discontinue claim P&G's Metamucil product causes excess gas and it Citrucel doesn't after P&G presented evidence that met NAD's standard for reopening a review. The industry self-regulation organization found GSK could no longer support its claim.

You may also be interested in...



Pepto-Bismol Ultra Works As Name But Not For P&G To Claim Twice Original Product's Strength

To understand how Pepto-Bismol Ultra could be considered twice as strong as original as stated on packaging, consumers would need to "carefully review the Drug Facts on the back of both" products and "recognize that the active ingredient in both products is 525 mg of bismuth subsalicylate" but Ultra's dose is half original's.

National Advertising Division’s Updated Procedures Allow Reopening Of Old Cases

Marketers now can petition NAD to reopen cases if they have new studies or other data supporting ad claims that were shot down by the watchdog group previously, though the bar for re-review is high, says NAD Director Laura Brett.

US Ad Watchdog Group May Allow Reopening Of Reviews With New Data

The private National Advertising Division is allowing marketers to petition to reopen closed cases if they have new studies or other data supporting ad claims, though the bar for re-review is high, says NAD Director Laura Brett.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS121411

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel